User contributions
Jump to navigation
Jump to search
- 02:08, 25 April 2024 diff hist +65 m Peripheral T-cell lymphoma
- 02:05, 25 April 2024 diff hist +50 m Peripheral T-cell lymphoma →Mogamulizumab monotherapy {{#subobject:8d8ae3|Regimen=1}}
- 02:04, 25 April 2024 diff hist +182 m Peripheral T-cell lymphoma →Lenalidomide monotherapy {{#subobject:372121|Regimen=1}}
- 02:00, 25 April 2024 diff hist +63 m Peripheral T-cell lymphoma →Forodesine monotherapy {{#subobject:2310b4|Regimen=1}}
- 01:58, 25 April 2024 diff hist +84 m Peripheral T-cell lymphoma →Chidamide monotherapy {{#subobject:5a869f|Regimen=1}}
- 01:56, 25 April 2024 diff hist +65 m Peripheral T-cell lymphoma
- 01:55, 25 April 2024 diff hist +63 m Peripheral T-cell lymphoma →DA-EPOCH {{#subobject:9b4e41|Regimen=1}}
- 01:53, 25 April 2024 diff hist +66 m Peripheral T-cell lymphoma →CHOEP-14 {{#subobject:e84b92|Regimen=1}}
- 01:53, 25 April 2024 diff hist +43 m Peripheral T-cell lymphoma →A-CHOP {{#subobject:75a3d2|Regimen=1}}
- 01:50, 25 April 2024 diff hist -14 m Urothelial carcinoma →References
- 01:49, 25 April 2024 diff hist +45 m Urothelial carcinoma →References
- 01:48, 25 April 2024 diff hist +45 m Urothelial carcinoma →References
- 01:44, 25 April 2024 diff hist +42 m Urothelial carcinoma →Pembrolizumab monotherapy {{#subobject:7fc2f6|Regimen=1}}
- 01:42, 25 April 2024 diff hist +61 m Urothelial carcinoma →Nivolumab monotherapy {{#subobject:23ugd2|Regimen=1}}
- 01:40, 25 April 2024 diff hist +45 m Bladder cancer →References
- 01:37, 25 April 2024 diff hist +890 m Multiple myeloma, relapsed-refractory
- 23:08, 24 April 2024 diff hist +1,996 m Chronic lymphocytic leukemia
- 23:01, 24 April 2024 diff hist +1 m Immune effector cells toxicity management →Consensus recommendations
- 23:01, 24 April 2024 diff hist +313 m Immune effector cells toxicity management →ASTCT
- 12:52, 24 April 2024 diff hist +1,681 m Nasopharyngeal carcinoma →Locally advanced disease, definitive chemoradiotherapy
- 12:51, 24 April 2024 diff hist +35,495 m Editing test page current
- 11:07, 24 April 2024 diff hist +2,292 m Acute myeloid leukemia →Relapsed or refractory, salvage therapy
- 11:06, 24 April 2024 diff hist +991 m Acute myeloid leukemia →MEC {{#subobject:48e49b|Regimen=1}}
- 11:03, 24 April 2024 diff hist +4,267 Acute myeloid leukemia →Azacitidine monotherapy {{#subobject:531b70|Regimen=1}}
- 17:34, 23 April 2024 diff hist +13 m Drug index →By Category
- 17:33, 23 April 2024 diff hist +4 m Drug index →Medications by Year of Approval
- 17:33, 23 April 2024 diff hist +42 m Drug index →Medications by Condition
- 17:27, 23 April 2024 diff hist +1,894 m Non-small cell lung cancer, EGFR-mutated →Cisplatin & Pemetrexed {{#subobject:26acke|Regimen=1}}
- 17:25, 23 April 2024 diff hist +1,184 m Non-small cell lung cancer, EGFR-mutated →Carboplatin & Pemetrexed {{#subobject:60cb1d|Regimen=1}}
- 17:09, 23 April 2024 diff hist +1 m Editing test page →External beam radiotherapy
- 17:09, 23 April 2024 diff hist +3 m Editing test page →External beam radiotherapy
- 17:02, 23 April 2024 diff hist +3 m Nasopharyngeal carcinoma →Radiotherapy
- 17:01, 23 April 2024 diff hist +3 m Nasopharyngeal carcinoma →Regimen variant #1, 30 mg/m2 weekly dosing {{#subobject:c0e2e2|Variant=1}}
- 17:00, 23 April 2024 diff hist +1 m Nasopharyngeal carcinoma →Regimen variant #4, 100 mg/m2 x 2 {{#subobject:b44282|Variant=1}}
- 17:00, 23 April 2024 diff hist 0 m Nasopharyngeal carcinoma →Radiotherapy
- 16:57, 23 April 2024 diff hist +3 m Head and neck cancer →Regimen variant #3, 30 mg/m2 weekly dosing {{#subobject:71731a|Variant=1}}
- 16:37, 23 April 2024 diff hist +1,226 m Non-small cell lung cancer, EGFR-mutated →Carboplatin & Pemetrexed {{#subobject:60cb1d|Regimen=1}}
- 16:24, 23 April 2024 diff hist +2,433 m Colorectal cancer, RAS wild-type →FOLFIRI & Cetuximab {{#subobject:11cf7b|Regimen=1}}
- 16:15, 23 April 2024 diff hist -1,072 m Colorectal cancer, RAS wild-type
- 12:44, 23 April 2024 diff hist +1,934 m Non-small cell lung cancer, nonsquamous →Carboplatin, Pemetrexed, Atezolizumab {{#subobject:a4hzv7|Regimen=1}}
- 12:34, 23 April 2024 diff hist +2,209 m Breast cancer, ER-positive →Anastrozole monotherapy {{#subobject:f8140f|Regimen=1}}
- 11:31, 23 April 2024 diff hist +150 m How I Treat →Transplantation
- 11:30, 23 April 2024 diff hist +172 m How I Treat →Myelodysplastic syndrome (MDS)
- 23:40, 22 April 2024 diff hist +30 m Classical Hodgkin lymphoma, pediatric
- 23:37, 22 April 2024 diff hist +7 m Small cell lung cancer →Preceding treatment
- 23:37, 22 April 2024 diff hist +6 m Prostate cancer →Subsequent treatment
- 23:16, 22 April 2024 diff hist -1 m Non-small cell lung cancer →Radiotherapy
- 23:15, 22 April 2024 diff hist -25 m Non-small cell lung cancer →Subsequent treatment
- 23:14, 22 April 2024 diff hist +13 m Non-small cell lung cancer →Subsequent treatment
- 23:12, 22 April 2024 diff hist +7 m Multiple myeloma - historical →Preceding treatment
- 23:11, 22 April 2024 diff hist +6 m Multiple myeloma - historical
- 23:10, 22 April 2024 diff hist +7 m Multiple myeloma - historical →Subsequent treatment
- 23:06, 22 April 2024 diff hist +1,516 N Nogapendekin alfa inbakicept (Anktiva) Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nogapendekin-alfa NCI Drug Dictionary]: A fusion protein complex composed of..." current
- 23:00, 22 April 2024 diff hist +74 m Drug index →N
- 13:14, 22 April 2024 diff hist +14 m Breast cancer, ER-positive →Adjuvant therapy, premenopausal
- 13:13, 22 April 2024 diff hist +2,251 m Breast cancer, ER-positive →Goserelin & Tamoxifen {{#subobject:23ef1e|Regimen=1}}
- 13:13, 22 April 2024 diff hist +12 m Breast cancer, ER-positive
- 13:12, 22 April 2024 diff hist +2,256 Breast cancer, ER-positive →Adjuvant therapy, premenopausal
- 13:09, 22 April 2024 diff hist +2,763 m Breast cancer, ER-positive →Anastrozole monotherapy {{#subobject:a052f4|Regimen=1}}
- 13:05, 22 April 2024 diff hist +2 m Breast cancer, ER-positive
- 13:05, 22 April 2024 diff hist +2,760 Breast cancer, ER-positive →Letrozole monotherapy {{#subobject:55e6f9|Regimen=1}}
- 12:52, 22 April 2024 diff hist +630 m Chronic myeloid leukemia →Imatinib monotherapy {{#subobject:917a16|Regimen=1}}
- 16:46, 21 April 2024 diff hist +6 m Ewing sarcoma
- 16:42, 21 April 2024 diff hist +7 m Esophageal cancer →Subsequent treatment
- 16:40, 21 April 2024 diff hist +7 m Diffuse large B-cell lymphoma →Subsequent treatment
- 16:38, 21 April 2024 diff hist +96 m Classical Hodgkin lymphoma
- 16:34, 21 April 2024 diff hist +7 m Breast cancer →Subsequent treatment
- 16:33, 21 April 2024 diff hist +7 m Breast cancer →Subsequent treatment
- 12:52, 21 April 2024 diff hist +7 m Breast cancer, ER-positive →Preceding treatment
- 12:48, 21 April 2024 diff hist +12 m Breast cancer - historical
- 12:46, 21 April 2024 diff hist -51 m Acute promyelocytic leukemia
- 12:42, 21 April 2024 diff hist +12 m Acute myeloid leukemia - historical →DAT {{#subobject:fc4f58|Regimen=1}}
- 20:15, 20 April 2024 diff hist +2,200 m Non-small cell lung cancer →Carboplatin & Docetaxel {{#subobject:bdce59|Regimen=1}}
- 20:06, 20 April 2024 diff hist +1,560 m Breast cancer - historical →STAMP-I {{#subobject:c08ab4|Regimen=1}}
- 20:05, 20 April 2024 diff hist -1,561 m Breast cancer - historical →VAP {{#subobject:4b99b8|Regimen=1}}
- 20:04, 20 April 2024 diff hist +513 m Breast cancer - historical →CTCb, then auto HSCT {{#subobject:02f569|Regimen=1}}
- 19:55, 20 April 2024 diff hist +2,042 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 19:55, 20 April 2024 diff hist -2,042 m Breast cancer - historical →CTCb, then auto HSCT {{#subobject:02f569|Regimen=1}}
- 19:54, 20 April 2024 diff hist +2,013 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 19:53, 20 April 2024 diff hist +1,366 m Breast cancer - historical →Mitoxantrone & Vinorelbine (MV) {{#subobject:eb48ba|Regimen=1}}
- 19:50, 20 April 2024 diff hist -2,555 m Breast cancer - historical →STAMP-I {{#subobject:c08ab4|Regimen=1}}
- 19:47, 20 April 2024 diff hist +61 m Breast cancer - historical →Metastatic disease, first-line therapy
- 18:32, 20 April 2024 diff hist +118 m Acute myeloid leukemia →Upfront induction therapy, standard and older "fit" patients
- 12:56, 20 April 2024 diff hist +44 m Esophageal cancer →References
- 12:54, 20 April 2024 diff hist +68 m Esophageal cancer
- 00:40, 20 April 2024 diff hist -140 m Cutaneous squamous cell carcinoma
- 00:39, 20 April 2024 diff hist +69 m Classical Hodgkin lymphoma
- 00:37, 20 April 2024 diff hist +845 m Classical Hodgkin lymphoma
- 00:37, 20 April 2024 diff hist -7 m Autologous HSCT →References
- 00:36, 20 April 2024 diff hist +63 m Autologous HSCT →Regimen {{#subobject:81ff2e|Variant=1}}
- 00:22, 20 April 2024 diff hist +35 m Head and neck cancer
- 00:20, 20 April 2024 diff hist +186 m Colorectal cancer
- 00:17, 20 April 2024 diff hist +251 m Non-small cell lung cancer
- 00:11, 20 April 2024 diff hist +69 m Malignant solid neoplasm, ERBB2-mutated →Trastuzumab emtansine monotherapy {{#subobject:0a0a41|Regimen=1}} current
- 00:10, 20 April 2024 diff hist +67 m Malignant solid neoplasm, ERBB2-mutated →Neratinib monotherapy {{#subobject:3c1a9c|Regimen=1}}
- 00:09, 20 April 2024 diff hist +1,507 Malignant solid neoplasm, ERBB2-mutated →Trastuzumab emtansine monotherapy {{#subobject:0a0a41|Regimen=1}}
- 00:03, 20 April 2024 diff hist +453 m Trastuzumab deruxtecan (Enhertu) current
- 23:55, 19 April 2024 diff hist 0 m Urothelial carcinoma
- 23:50, 19 April 2024 diff hist +3 m Melanoma →Regimen variant #1, 2 mg/kg q3wk {{#subobject:25a9fe|Variant=1}}
- 23:49, 19 April 2024 diff hist +3 m Melanoma →Regimen variant #2, indefinite {{#subobject:722e51|Variant=1}}